New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
13:27 EDTSLXPFDA approves anti-diarrheal drug for HIV/AIDS patients distributed by Salix
The U.S. Food and Drug Administration approved Fulyzaq to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection. Before treating patients with Fulyzaq, health care professionals should conduct proper testing to confirm the diarrhea is not caused by an infection or a gastrointestinal disease. Common side effects reported in patients taking Fulyzaq in the clinical trial were upper respiratory tract infection, bronchitis, cough, flatulence, and increased levels of the liver enzyme bilirubin. Fulyzaq is distributed by Salix Pharmaceuticals under license from Napo Pharmaceuticals.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent SLXP news | >>
November 7, 2014
12:20 EDTSLXPOn The Fly: Midday Wrap
Stocks on Wall Street opened in relatively quiet fashion and trading has remained that way throughout the morning. The highly anticipated nonfarm payrolls report showed fewer than expected jobs were added last month, but the figures from the prior two months were also upwardly revised. The market has moved in a narrow range and for the most part has remained near the flat line, with the S&P and Dow little changed and the Nasdaq lagging near noon. ECONOMIC EVENTS: In the U.S., nonfarm payrolls rose 214K in October, which was below the consensus estimate for 235K jobs to have been added. However, back revisions boosted September's job gain to 256K from the 248K previously reported, while August's prior 180K reading was pushed up to 203K. The unemployment rate slid to 5.8% from 5.9%, its lowest level since July 2008. Later this afternoon, the Federal Reserve Board’s report on consumer credit growth in September is expected, with total credit projected to grow $16B. COMPANY NEWS: Shares of Disney (DIS) led all decliners on the Dow, as the stock fell 2.5% after the company reported earnings and revenue for its fourth quarter that were nearly in-line with consensus estimates. Along with its report, the company confirmed 2015's Star Wars movie will be entitled "The Force Awakens" and announced plans for another sequel in the "Toy Story" franchise. MAJOR MOVERS: Among the notable gainers was ChannelAdvisor (ECOM), which rose 46% after delivering generally in-line Q3 results, giving better than expected fiscal year revenue guidance and announcing the acquisition of U.K. based E-Tale Holdings. Also higher were shares of Sears Holdings (SHLD), which jumped 26% after the company disclosed it is actively exploring a REIT transaction involving 200-300 owned properties through a rights offering to shareholders. Among the noteworthy losers was Salix (SLXP), which plunged 36% and was downgraded by at least four firms after the company reported worse than expected Q3 results, gave lower than expected guidance and announced its CFO had resigned amid the company revising its view of the current inventory levels for its drugs. Also lower were shares of Intercept Pharmaceuticals (ICPT), which fell 33% after results from the FLINT trial evaluating obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH, were published in The Lancet. Oppenheimer said it believes that data disclosed last night was in-line with previous data from Intercept, but that a Bloomberg story "cherry picked" negative aspects of the data, contributing to the share decline. INDEXES: Near midday, the Dow was virtually unchanged at 17,555.12, the Nasdaq was down 13.72, or 0.3%, to 4,624.75, and the S&P 500 was up 0.42, or 0.02%, to 2,031.63.
10:00 EDTSLXPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTSLXPOn The Fly: Pre-market Movers
HIGHER: Sears (SHLD), up 22.5% after reporting Q3 same-store sales were flat with prior year, saying company is actively exploring a REIT transaction involving 200-300 owned properties through a rights offering... Gap (GPS), up 2.9% after reporting October same-store sales fell 3%, giving Q3 EPS guidance that beat estimates... Zynga (ZNGA), up 9%, upgraded at Needham following the company's Q3 earnings report... King Digital (KING), up 8.6% after Q3 results top expectations, company announces $150M share repurchase program... ChannelAdvisor (ECOM), up 30% after earnings, guidance, announcing acquisition of U.K. based E-Tale Holdings... Rockwell Medical (RMTI), up 25% after FDA committee recommends Triferic to treat iron loss in certain patients with chronic kidney disease... Repros Therapeutics (RPRX), up 23% following meeting with FDA regarding Androxal NDA filing. LOWER: Salix (SLXP), down 35%, downgraded at Mizuho, Stifel and William Blair after the company reported worse than expected Q3 earnings, gave lower than expected guidance and announced its CFO had resigned... Intercept (ICPT), down 19% after FLINT trial results published... CTI BioPharma (CTIC), down 20% after filing convertible preferred stock offering... Transocean (RIG), down 5% after delaying its Q3 earnings release and conference call, stating the company expects Q3 to include a non-cash charge of $1.97B for impairment of goodwill... General Mills (GIS), down 4% after lowering FY15 outlook. DOWN AFTER EARNINGS: Abercrombie & Fitch (ANF), down 12.6%... Ubiquiti Networks (UBNT), down 17%... Arista Networks (ANET), down 10.5%... First Solar (FSLR), down 6%... Magnum Hunter (MHR), down 2%.
08:35 EDTSLXPSalix price target lowered to $117 from $192 at Canaccord
Subscribe for More Information
08:29 EDTSLXPSalix downgraded to Neutral from Buy at Roth Capital
Note this is the fourth downgrade of the day.
07:59 EDTSLXPSalix volatility elevated into accounting revision
Salix November and December call option implied volatility of 58 compares to its 26-week average of 47 according to Track Data, suggesting large near term price movement after announcing an accounting revision that showed sales of its drugs not as strong as Wall Street's expectations.
07:44 EDTSLXPSalix pullback in shares overdone, says Leerink
Subscribe for More Information
07:18 EDTSLXPSalix product franchise can still create value, says Piper Jaffray
Subscribe for More Information
07:14 EDTSLXPSalix sell-off overdone, says Brean Capital
Subscribe for More Information
07:06 EDTSLXPSalix downgraded to Market Perform from Outperform at William Blair
Subscribe for More Information
06:10 EDTSLXPSalix downgraded to Hold from Buy at Stifel
Subscribe for More Information
06:08 EDTSLXPSalix downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Salix to Neutral with an $88 price target citing a lack of visibility into inventory issues following the company's Q3 results.
November 6, 2014
18:39 EDTSLXPOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTSLXPSalix appoints Timothy Creech as acting CFO
Salix Pharmaceuticals announced the appointment of Timothy J. Creech as Acting CFO of the company, effective immediately. He succeeds Adam C. Derbyshire, who resigned his position at the company. Creech, who joined the company in 2007, has most recently been serving as the company’s SVP, finance and administrative services. The company has retained Korn Ferry to assist the company in identifying an individual to serve as the company’s CFO in a permanent capacity.
16:19 EDTSLXPSalix sees FY14 EPS about $5.20, consensus $6.17
Sees FY14 revenue approximately $1.4B, consensus $1.59B.
16:18 EDTSLXPSalix sees Q4 EPS about $1.16, consensus $1.95
Subscribe for More Information
16:16 EDTSLXPSalix reports Q3 EPS $1.53, consensus $1.55
Reports Q3 revenue $354.72M, consensus $392.36M.
15:27 EDTSLXPNotable companies reporting after market close
Subscribe for More Information
15:13 EDTSLXPAmerican Association for Study of Liver Diseases to hold a meeting
Subscribe for More Information
10:05 EDTSLXPActavis talks to buy Salix put on hold, Bloomberg says
Subscribe for More Information
1 | 2 | all recent SLXP news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use